3.連結財務諸表及び主な注記
(1)連結貸借対照表
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2025年3月31日)
|
当連結会計年度
(2026年3月31日)
|
|
資産の部
|
|
|
|
|
流動資産
|
|
|
|
|
|
現金及び預金
|
2,850,379
|
2,627,404
|
|
|
|
受取手形及び売掛金
|
1,297,618
|
1,135,657
|
|
|
|
電子記録債権
|
106,871
|
234,683
|
|
|
|
商品及び製品
|
239,420
|
215,312
|
|
|
|
仕掛品
|
1,416,295
|
1,561,467
|
|
|
|
原材料及び貯蔵品
|
500,000
|
609,808
|
|
|
|
その他
|
175,205
|
225,135
|
|
|
|
貸倒引当金
|
△115
|
△109
|
|
|
|
流動資産合計
|
6,585,675
|
6,609,359
|
|
|
固定資産
|
|
|
|
|
|
有形固定資産
|
|
|
|
|
|
|
建物及び構築物
|
2,962,565
|
3,014,264
|
|
|
|
|
|
減価償却累計額
|
△2,048,538
|
△2,163,411
|
|
|
|
|
|
建物及び構築物(純額)
|
914,027
|
850,852
|
|
|
|
|
機械装置及び運搬具
|
3,463,674
|
3,454,819
|
|
|
|
|
|
減価償却累計額
|
△3,029,173
|
△2,988,423
|
|
|
|
|
|
機械装置及び運搬具(純額)
|
434,501
|
466,395
|
|
|
|
|
土地
|
1,457,525
|
1,669,535
|
|
|
|
|
リース資産
|
217,168
|
216,199
|
|
|
|
|
|
減価償却累計額
|
△166,568
|
△163,719
|
|
|
|
|
|
リース資産(純額)
|
50,600
|
52,480
|
|
|
|
|
建設仮勘定
|
19,311
|
26,076
|
|
|
|
|
その他
|
630,042
|
691,350
|
|
|
|
|
|
減価償却累計額
|
△561,805
|
△610,184
|
|
|
|
|
|
その他(純額)
|
68,236
|
81,166
|
|
|
|
|
有形固定資産合計
|
2,944,202
|
3,146,505
|
|
|
|
無形固定資産
|
|
|
|
|
|
|
特許権
|
10,050
|
9,288
|
|
|
|
|
リース資産
|
2,597
|
13,326
|
|
|
|
|
その他
|
20,723
|
21,014
|
|
|
|
|
無形固定資産合計
|
33,371
|
43,629
|
|
|
|
投資その他の資産
|
|
|
|
|
|
|
投資有価証券
|
124,970
|
126,859
|
|
|
|
|
出資金
|
130
|
130
|
|
|
|
|
繰延税金資産
|
97,934
|
173,211
|
|
|
|
|
その他
|
62,556
|
71,486
|
|
|
|
|
貸倒引当金
|
△5,993
|
△5,993
|
|
|
|
|
投資その他の資産合計
|
279,598
|
365,693
|
|
|
|
固定資産合計
|
3,257,172
|
3,555,828
|
|
|
資産合計
|
9,842,848
|
10,165,188
|
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2025年3月31日)
|
当連結会計年度
(2026年3月31日)
|
|
負債の部
|
|
|
|
|
流動負債
|
|
|
|
|
|
支払手形及び買掛金
|
163,081
|
154,172
|
|
|
|
電子記録債務
|
327,261
|
276,860
|
|
|
|
1年内返済予定の長期借入金
|
552,060
|
523,550
|
|
|
|
リース債務
|
13,088
|
20,919
|
|
|
|
未払法人税等
|
144,385
|
20,591
|
|
|
|
賞与引当金
|
138,296
|
96,211
|
|
|
|
その他
|
301,091
|
266,547
|
|
|
|
流動負債合計
|
1,639,264
|
1,358,852
|
|
|
固定負債
|
|
|
|
|
|
長期借入金
|
894,330
|
940,570
|
|
|
|
リース債務
|
30,543
|
37,515
|
|
|
|
再評価に係る繰延税金負債
|
23,719
|
23,719
|
|
|
|
株式給付引当金
|
118,936
|
122,641
|
|
|
|
退職給付に係る負債
|
427,738
|
429,673
|
|
|
|
その他
|
515
|
515
|
|
|
|
固定負債合計
|
1,495,783
|
1,554,636
|
|
|
負債合計
|
3,135,047
|
2,913,489
|
|
純資産の部
|
|
|
|
|
株主資本
|
|
|
|
|
|
資本金
|
1,939,834
|
1,939,834
|
|
|
|
資本剰余金
|
517,064
|
517,091
|
|
|
|
利益剰余金
|
4,328,704
|
4,801,217
|
|
|
|
自己株式
|
△256,105
|
△282,571
|
|
|
|
株主資本合計
|
6,529,498
|
6,975,572
|
|
|
その他の包括利益累計額
|
|
|
|
|
|
その他有価証券評価差額金
|
60,473
|
61,717
|
|
|
|
土地再評価差額金
|
26,474
|
26,474
|
|
|
|
為替換算調整勘定
|
91,354
|
187,935
|
|
|
|
その他の包括利益累計額合計
|
178,302
|
276,126
|
|
|
純資産合計
|
6,707,800
|
7,251,699
|
|
負債純資産合計
|
9,842,848
|
10,165,188
|
E00584
35830
オーベクス株式会社
AuBEX CORPORATION
通期第1号参考様式 [日本基準](連結)
Japan GAAP
true
cte
cte
2025-04-01
2026-03-31
FY
2026-03-31
2024-04-01
2025-03-31
2025-03-31
1
false
false
false
35830
2026-05-12
35830
2025-04-01
2026-03-31
35830
2025-04-01
2026-03-31
jppfs_cor:CapitalStockMember
35830
2025-04-01
2026-03-31
jppfs_cor:CapitalSurplusMember
35830
2025-04-01
2026-03-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
35830
2025-04-01
2026-03-31
jpcrp_cor:ReconcilingItemsMember
35830
2025-04-01
2026-03-31
jpcrp_cor:ReportableSegmentsMember
35830
2025-04-01
2026-03-31
jppfs_cor:RetainedEarningsMember
35830
2025-04-01
2026-03-31
jppfs_cor:RevaluationReserveForLandMember
35830
2025-04-01
2026-03-31
jppfs_cor:ShareholdersEquityMember
35830
2025-04-01
2026-03-31
jppfs_cor:TreasuryStockMember
35830
2025-04-01
2026-03-31
tse-acedjpfr-35830:MedicalProductsReportableSegmentsMember
35830
2025-04-01
2026-03-31
tse-acedjpfr-35830:TechnologicalProductsReportableSegmentsMember
35830
2025-04-01
2026-03-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
35830
2025-04-01
2026-03-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
35830
2026-03-31
35830
2026-03-31
jppfs_cor:CapitalStockMember
35830
2026-03-31
jppfs_cor:CapitalSurplusMember
35830
2026-03-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
35830
2026-03-31
jpcrp_cor:ReconcilingItemsMember
35830
2026-03-31
jpcrp_cor:ReportableSegmentsMember
35830
2026-03-31
jppfs_cor:RetainedEarningsMember
35830
2026-03-31
jppfs_cor:RevaluationReserveForLandMember
35830
2026-03-31
jppfs_cor:ShareholdersEquityMember
35830
2026-03-31
jppfs_cor:TreasuryStockMember
35830
2026-03-31
tse-acedjpfr-35830:MedicalProductsReportableSegmentsMember
35830
2026-03-31
tse-acedjpfr-35830:TechnologicalProductsReportableSegmentsMember
35830
2026-03-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
35830
2026-03-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
35830
2024-04-01
2025-03-31
35830
2024-04-01
2025-03-31
jppfs_cor:CapitalStockMember
35830
2024-04-01
2025-03-31
jppfs_cor:CapitalSurplusMember
35830
2024-04-01
2025-03-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
35830
2024-04-01
2025-03-31
jpcrp_cor:ReconcilingItemsMember
35830
2024-04-01
2025-03-31
jpcrp_cor:ReportableSegmentsMember
35830
2024-04-01
2025-03-31
jppfs_cor:RetainedEarningsMember
35830
2024-04-01
2025-03-31
jppfs_cor:RevaluationReserveForLandMember
35830
2024-04-01
2025-03-31
jppfs_cor:ShareholdersEquityMember
35830
2024-04-01
2025-03-31
jppfs_cor:TreasuryStockMember
35830
2024-04-01
2025-03-31
tse-acedjpfr-35830:MedicalProductsReportableSegmentsMember
35830
2024-04-01
2025-03-31
tse-acedjpfr-35830:TechnologicalProductsReportableSegmentsMember
35830
2024-04-01
2025-03-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
35830
2024-04-01
2025-03-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
35830
2025-03-31
35830
2025-03-31
jppfs_cor:CapitalStockMember
35830
2025-03-31
jppfs_cor:CapitalSurplusMember
35830
2025-03-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
35830
2025-03-31
jpcrp_cor:ReconcilingItemsMember
35830
2025-03-31
jpcrp_cor:ReportableSegmentsMember
35830
2025-03-31
jppfs_cor:RetainedEarningsMember
35830
2025-03-31
jppfs_cor:RevaluationReserveForLandMember
35830
2025-03-31
jppfs_cor:ShareholdersEquityMember
35830
2025-03-31
jppfs_cor:TreasuryStockMember
35830
2025-03-31
tse-acedjpfr-35830:MedicalProductsReportableSegmentsMember
35830
2025-03-31
tse-acedjpfr-35830:TechnologicalProductsReportableSegmentsMember
35830
2025-03-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
35830
2025-03-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
35830
2024-03-31
35830
2024-03-31
jppfs_cor:CapitalStockMember
35830
2024-03-31
jppfs_cor:CapitalSurplusMember
35830
2024-03-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
35830
2024-03-31
jppfs_cor:RetainedEarningsMember
35830
2024-03-31
jppfs_cor:RevaluationReserveForLandMember
35830
2024-03-31
jppfs_cor:ShareholdersEquityMember
35830
2024-03-31
jppfs_cor:TreasuryStockMember
35830
2024-03-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
35830
2024-03-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
iso4217:JPY
xbrli:pure